Rofecoxib
Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2; it exhibits anti-inflammatory, analgesic, antiepileptic/anticonvulsant, and chemopreventive activities but is no longer clinically administered. Rofecoxib inhibits the formation of bladder tumors in FHIT models of bladder cancer carcinogenesis. Additionally, rofecoxib increases seizure threshold in an adenosine-dependent manner in vivo.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18964254
| Cas No. |
162011-90-7 |
|---|---|
| Purity |
≥98% |
| Formula |
C17H14O4S |
| Formula Wt. |
314.36 |
| Chemical Name |
4-[4-(Methylsulfonyl)-phenyl]-3-phenyl-2(5H)- furanone |
| IUPAC Name |
3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one |
| Synonym |
Vioxx |
| Melting Point |
207-208°C |
| Solubility |
Slightly soluble in methanol and acetone. Insoluble in water. |
| Appearance |
Slightly yellowish powder |
DArca D, LeNoir J, Wildemore B, et al. Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor. Urol Oncol. 2010 Mar-Apr;28(2):189-94. PMID: 19372053.
Akula KK, Dhir A, Kulkarni SK. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism. Epilepsy Res. 2008 Jan;78(1):60-70. PMID: 18054463.
